Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anti-platelet Therapy Clear all
Terminated Phase 4 Interventional Results available

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study

NCT01452152
View directory record Official record
Conditions
Cardiovascular Diseases, Acute Coronary Syndrome
Interventions
clopidogrel, prasugrel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 74 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Newark, Delaware • Baltimore, Maryland • Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Phase 4 Interventional Results available

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

NCT04483583
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 60mg, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Phase 4 Interventional Results available

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

NCT02548650
View directory record Official record
Conditions
Myocardial Infarction, Diabetes Mellitus, Peripheral Arterial Disease
Interventions
Vorapaxar, Clopidogrel, Aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Phase 2 Interventional Results available

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

NCT00061373
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Aspirin, tinzaparin sodium, eptifibatide
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Phase 4 Interventional Results available

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

NCT04006288
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Prasugrel, ticagrelor, aspirin, rivaroxaban
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 28, 2026, 11:30 AM EDT
Not listed Phase 4 Interventional

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

NCT03150667
View directory record Official record
Conditions
Chronic Kidney Diseases, Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 28, 2026, 11:30 AM EDT
Not listed Phase 4 Interventional Results available

CYPRESS - CYPHER for Evaluating Sustained Safety

NCT00954707
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel & Aspirin, Prasugrel & Aspirin, Placebo & Aspirin
Drug
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
2,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT01151423
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Phase 1 Interventional

Anti-platelet + Pembro for H&N Tumors

NCT03245489
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Clopidogrel, acetylsalicylic acid
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 28, 2026, 11:30 AM EDT
Active, not recruiting Phase 3 Interventional

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

NCT05047172
View directory record Official record
Conditions
Intracranial Arteriosclerosis, Stroke
Interventions
Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
114
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 11:30 AM EDT
Completed No phase listed Observational

Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

NCT00998127
View directory record Official record
Conditions
Medication Non-adherence, Stent Thrombosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
5,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Phase 2 Interventional Results available

Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

NCT00642174
View directory record Official record
Conditions
Diabetes Mellitus, Coronary Artery Disease
Interventions
prasugrel, Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Phase 2 Interventional

Daclizumab to Treat Chronic Immune Thrombocytopenia

NCT00049725
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Daclizumab
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 11:30 AM EDT
Terminated Phase 2 Interventional Results available

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
Drug · Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
75 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Phase 4 Interventional Results available

Vorapaxar on Thrombin Generation and Coagulability

NCT03207451
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Vascular Disease, Myocardial Infarction
Interventions
Vorapaxar, Vorapaxar and Aspirin, Vorapaxar and Clopidogrel, Vorapaxar, Aspirin, and Clopidogrel
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 28, 2026, 11:30 AM EDT
Terminated Not applicable Interventional

Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury

NCT01810276
View directory record Official record
Conditions
Traumatic Head Injury, Intracranial Hemmorhage, Anti-platelet Therapy
Interventions
Saline, Platelets
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Not applicable Interventional Results available

COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT

NCT01925794
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
COBRA PzF
Device
Lead sponsor
CeloNova BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
22
States / cities
Bakersfield, California • Miami Beach, Florida • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 28, 2026, 11:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation

NCT03746782
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Flow Cytrometry; Thrombin Generation Assay
Diagnostic Test
Lead sponsor
CirQuest Labs, LLC
Other
Eligibility
18 Years to 74 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 28, 2026, 11:30 AM EDT
Completed No phase listed Observational

Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

NCT01647568
View directory record Official record
Conditions
Post-polypectomy Bleeding, Anti-platelet Therapy, Colonoscopy
Interventions
Not listed
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Oct 28, 2026, 11:30 AM EDT
Completed No phase listed Observational

Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy

NCT00625248
View directory record Official record
Conditions
Bleeding
Interventions
Antithrombotics
Drug
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 28, 2026, 11:30 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

NCT00547066
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune
Interventions
veltuzumab
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Riverdale, Georgia • Tucker, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry

NCT04822363
View directory record Official record
Conditions
Platelet Activation Testing Before/After Anti-platelet Therapy, Healthy
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer

NCT00003082
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
monoclonal antibody A27.15, monoclonal antibody E2.3
Biological
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Oct 28, 2026, 11:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)

NCT00799396
View directory record Official record
Conditions
Platelet Aggregation Inhibitors, Coronary Heart Disease
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 28, 2026, 11:30 AM EDT